Menopause care is far from a niche concern—it’s a global health and economic issue that impacts millions of women every year. Yet, as Anne Fulenwider and Monica Molenaar, co-founders of Alloy Women's Health, found out when pitching their startup, early investors often dismissed it as "niche."
Fast forward to 2024, and Alloy has proven the skeptics wrong, securing $16M in Series A funding to transform menopause care. The stats tell the story:
1.3M women enter menopause annually in the U.S.
Less than 2% receive proper care, leaving many waiting years for relief.
It’s a $17B global market—anything but niche.
Since launching, Alloy has delivered measurable impact:
300% year-over-year customer growth
Tens of thousands of women treated
Achieved profitability in just three years
This new funding will fuel Alloy’s expansion into midlife wellness products, ensuring more women can access the care they need to feel their best. It’s a significant win for women’s health, but the work doesn’t stop here. The space still needs more investors willing to champion innovative solutions for women’s unique health challenges.
As Sarah Anto, a supporter of women founders through the FundHER accelerator program, said: "Who’s ready to step up and invest in the future of women’s health?"
Let’s change the narrative. Menopause care isn’t niche—it’s necessary.
Comments